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Epidemiological studies have demonstrated that 15 different mucosal human papillomavirus (HPV) types of the genus alpha of the HPV
phylogetic tree are classified as high risk for cervical cancer development. Three additional HPV types of the same genus, HPV26, 53 and 66, are
classified as probable high-risk types. In this study, we have characterized the biological properties of the E7 oncoproteins from these three HPV
types. All of the corresponding E7 proteins were able to associate with retinoblastoma protein (pRb) and up-regulated the expression of several
positive cell cycle regulators, i.e. CDK2, cyclin A and cylin E. However, HPV26 E7 appears to be more efficient than HPV53 and 66 E7 in up-
regulating the transcription of cyclin A. Unlike E7 from the high-risk type HPV16 protein, HPV26, 53 and 66 did not efficiently promote pRb
degradation. In addition, E7 from these viruses was able to promote proliferation of primary human keratinocytes and circumvent G1 arrest
imposed by overexpression of p16INK4a, but with less efficiency than the high-risk HPV16 E7. Together, our data show that in vitro properties of
these E7 proteins correlate with the epidemiological classification of HPV26, 53 and 66 as HPV types with an intermediate risk for cervical cancer
development.
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Cervical cancer affects more than 400,000 women in the
world each year and represents the second most common
malignancy found after breast cancer (Pisani et al., 2002). It is
now well demonstrated that certain types of human papilloma-
virus (HPV) from the genus alpha of the HPV phylogenetic tree,
referred to as high-risk types, are the etiological cause of cervical
cancer (Zur Hausen, 2002). A recent survey of 11 case-control
studies in nine countries showed that 15 different HPVs were
classified as high-risk types, namely 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73 and 82. In addition three HPV types
from the same genus, HPV26, 53 and 66, were classified as
probable high-risk types (Munoz et al., 2003). Several other
mucosal HPV types, e.g. HPV6 and HPV11, were considered
low-risk types, which are normally associated with benign⁎ Corresponding author. Fax: +33 4 72738442.
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subgroup, HPV16 andHPV18 are themost prevalent type in pre-
malignant and malignant cervical lesions worldwide (Clifford et
al., 2005; Munoz et al., 2003). Therefore, until now the majority
of studies have focused mainly on these two HPV types. Several
independent studies have demonstrated that the products of two
early genes, E6 and E7, are the main transforming proteins of the
virus (Munger et al., 2004). HPV16 E7 together with E6 can
efficiently immortalize human primary keratinocytes that are
naturally infected by the virus. This event is explained by the
ability of E6 and E7 to interact with and alter the functions of
several cellular proteins, leading to the deregulation of the cell
cycle and apoptosis (Munger et al., 2004).
Retinoblastoma protein (pRb) is a key player in cell cycle
regulation. It negatively regulates the activity of several trans-
cription factors, including members of the E2F family (Dimova
and Dyson, 2005). In quiescent cells, the hypophosphorylated
form of pRb binds E2F, inhibiting its transcription activity.
When G0 phase cells are exposed to mitogenic signals, G1-
2 M. Mansour et al. / Virology 367 (2007) 1–9specific D-type cyclins (D1, D2 and D3) are expressed and
activate the cyclin-dependent kinases 4 and 6 (CDK4 and
CDK6), which in turn phosphorylate pRb in mid-G1 phase
(Sherr, 1996). This event leads to the release of active E2F,
which promotes the transcription of a group of genes that
encode proteins essential for cell cycle progression. This group
includes cyclin E and A, which, after association with CDK2,
phosphorylate pRb in the successive cell cycle phases. HPV16
E7 associates with pRb promoting its degradation via the
proteasomes (Jones and Munger, 1997). The interaction of
HPV16 E7 with pRb, analogously to the CDK-mediated
phosphorylation, results in the release of active E2Fs and
stimulation of S-phase entry, even in the absence of mitogenic
signals and active CDK complexes (Munger et al., 2004).
Similarly to HPV16 E7, E6 also has the ability to target the
product of a tumor suppressor gene. HPV16 E6 associates with
and neutralizes the function of p53, resulting in a complete loss
of the p53-dependent apoptotic response (Mantovani and Banks,
2001). E6 mediates p53 degradation by interacting with a
100 kDa cellular protein, termed E6 associated protein (E6AP),
which functions as an ubiquitin protein ligase (reviewed in
Mantovani and Banks, 2001). The ability to promote p53
degradation is an exclusive property of E6 from the high-risk
HPV types, underlining the importance of this event in HPV-
mediated carcinogenesis.
A recent comparative analysis of 19 different mucosal HPV
types revealed that the ability of each HPV type to induce p53
degradation and immortalization of primary keratinocytes
correlated with its phylogenetic classification and carcinogenic
potential indicated by epidemiological studies (Hiller et al.,
2006). The only exceptions found were HPV53 and 66. The E6
of these two HPV types displayed similar biological properties
to the ones of the other high-risk HPV types (Hiller et al., 2006).
In addition, the introduction of the entire genome into primary
keratinocytes led to their immortalization. However, based on
their prevalence in cervical carcinomas, they have been
classified, together with HPV26, as intermediate-risk HPV
types (Munoz et al., 2003). Thus, in an in vivo context,
additional viral functions appear to be responsible for the
differing levels of carcinogenic risk of closely phylogenetically
related HPV types. Since studies on HPV16 E7 have demon-
strated the crucial role of this oncoprotein in the promotion of
cellular transformation, the intermediate risk of HPV26, 53, and
66may be determined by differences in the properties of their E7
proteins. We have therefore characterized the biological
functions of the E7 protein of HPV26, 53 and 66 in primary
human fibroblasts and keratinocytes. Our data show that E7
from these three viruses displays lower activities than HPV16 E7
in deregulating cell cycle control.
Results
E7 proteins from HPV26, 53 and 66 associate with pRB
without efficient induction of its degradation
Studies on HPV16 have demonstrated that inactivation of the
pRb pathway is a key event in E7-induced proliferation (Mungeret al., 2004). Therefore, we first compared the efficiency of
HPV6, 16, 26, 53 and 66 E7s in binding pRb in a GST-pull down
assay. Equal amounts of the bacterial recombinant GST-E7
proteins were immobilized on glutathione-sepharose beads and
incubated with protein extracts of HaCaT cells. After extensive
washing, the amount of endogenous pRb bound to the beads was
analyzed by immunoblotting. As shown in Figs. 1A and B,
HPV26, 53 and 66 E7 proteins bound pRb with efficiency
similar to HPV16 E7, while HPV6 E7 resulted to have the lowest
affinity for pRb.
Next, we determined whether the interaction of these three
E7 proteins with pRb could promote its degradation, as
previously shown for HPV16 E7. For this purpose, HPV26,
53 and 66 E7 genes were cloned into a retroviral vector and
transduced into primary human keratinocytes. Expression of
viral genes was verified by RT-PCR (Fig. 1C). Keratinocytes
transduced with an empty retrovirus (pLXSN) or retroviruses
expressing HPV16, 26, 53 and 66 E7 genes were cultured in a
medium containing cycloheximide to inhibit protein synthesis.
pRb half-life was determined by immunoblotting. Unlike
HPV16 E7, none of the E7 proteins of the intermediate-risk
HPV types was able to destabilize pRb (Figs. 1D and E). Thus,
HPV26, 53 and 66 E7 target pRb with a different mechanism
than HPV16 E7.
E7 proteins from HPV26, 53 and 66 alter the expression of
several cell cycle regulators in primary human keratinocytes
Inactivation of pRb has consequential effects on the ex-
pression of positive and negative cell cycle regulators. There-
fore, we determined the levels of several cellular proteins
involved in cell cycle control in keratinocytes expressing the
viral genes. Keratinocytes expressing the different E7 genes had
higher levels of CDK2 and cyclin E than did the control cells
(pLXSN keratinocytes) (Figs. 2A and B). Also, cyclin A levels
were up-regulated in the keratinocytes expressing the E7 genes
in comparison to the controls (pLXSN) (Figs. 2A and B). How-
ever, we observed that cyclin A protein levels were strongly
elevated in HPV16 and 26 E7-expressing cells, but less in cells
containing HPV53 and 66 E7 (Figs. 2A and B). The difference in
the amount of cyclin A protein in the different cells may be due
to the level of mRNA. To evaluate this hypothesis, we
determined the cyclin A mRNA levels by real-time PCR. As
shown in Fig. 2C, cyclin A mRNA and protein levels tightly
correlated. Thus, it appears that HPV16 and 26 are more efficient
than HPV53 and 66 in activating the transcription of cyclin A,
although all four E7 keratinocytes had higher levels of cyclin A
than the mock cells (pLXSN) (Figs. 2A–C). The immunoblot
analysis also revealed that the CDK inhibitor, p21WAF1, is up-
regulated in the keratinocytes expressing the four E7 proteins
(Figs. 2A and B). Next we determined the effect of E7 from the
low-risk HPV6 type on cell cycle regulators. Primary keratino-
cytes were transduced with recombinant retrovirus and the E7
expression was determined by RT-PCR (Fig. 2D). No significant
changes on cyclin E, CDK2 and p21WAF1 levels were detected
in keratinocytes expressing the low-risk HPV6 E6 in comparison
to mock cells (pLXSN) (Figs. 2E–F).
Fig. 1. Ability of HPV26, HPV53, HPV66 E7 to target pRb. (A) Interaction of HPV26, HPV53, HPV66 E7 with pRb in a GST pull-down assay. HaCaT cellular
extracts (600 μg) were incubated with beads containing approximately 1 μg of the different fusion proteins. After extensive washing of the beads, the amount of pRb
associated with the different GST-E7 proteins was determined by immunoblot analysis with a specific anti-pRb antibody. (B) Quantification of the pRb amount
associated with GST-E7 proteins. Signals of immunoblotting of two independent experiments were quantified by Fluor-S™MultiImager (BioRad). (C) Determination
of HPV16, HPV26, HPV53 and HPV66 E7 mRNA expression in primary keratinocytes by RT-PCR. Total RNAwas extracted from keratinocytes infected with the
indicated retroviruses and, after cDNA synthesis, PCR was performed with primers specific for each E7. In the case of control cells (pLXSN), PCR was performed with
a mixture of all E7 primers. (D and E) Ability of HPV26, HPV53 and HPV66 E7 to promote pRb degradation. The indicated keratinocytes were cultured in a medium
containing cycloheximide. The levels of pRb and β-actin (loading control) were determined by immunoblotting (D) and the amount of pRb and β-tubulin was
quantified by Fluor-S™MultiImager (BioRad) in three independent experiments (E). A representative experiment is shown in panel D, while the mean data of three
independent experiments are shown in panel E.
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Fig. 2. HPV26, 53 and 66 E7 interfere with cell cycle regulation. (A) Determination of intracellular levels of positive and negative cell cycle regulators in E7-
expressing keratinocytes. Total protein extracts (50 μg) from the indicated keratinocytes were applied to an SDS-10% polyacrylamide gel, transferred onto a PVDF
membrane, and incubated with an anti-cyclin A, -cyclin E, -CDK2, -p21WAF1/CIP1 or -β-tubulin antibody. The β-tubulin signal was used as a loading control. (B)
Quantification of the intracellular levels of positive and negative cell cycle regulators. Signals of immunoblotting of two independent experiments were quantified by
Fluor-S™MultiImager (BioRad). (C) Real-time PCR of cyclin A mRNA levels in E7-expressing keratinocytes. Total RNAwas prepared and quantified by real-time
PCR. (D) Determination of HPV6 and HPV16 E7 mRNA expression in primary keratinocytes by RT-PCR. Total RNAwas extracted from keratinocytes infected with
the indicated retroviruses and, after cDNA synthesis, PCR was performed with primers specific for each E7. In the case of control cells (pLXSN), PCR was performed
with a mixture of all E7 primers. (E) Determination of intracellular levels of positive and negative cell cycle regulators in HPV6 and HPV16 E7-expressing
keratinocytes. Total protein extracts (50 μg) from the indicated keratinocytes were applied to an SDS-10% polyacrylamide gel, transferred onto a PVDF membrane,
and incubated with an anti-cyclin E, -CDK2, -p21WAF1/CIP1 or -β-actin antibody. The β-acting signal was used as a loading control. (F) Quantification of the
intracellular levels of positive and negative cell cycle regulators. Signals of immunoblotting of two independent experiments were quantified by Fluor-S™
MultiImager (BioRad).
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the functions of p21WAF1 (Funk et al., 1997; Jones et al.,
1997). Therefore, we next determined whether E7 of HPV26,
53 and 66 are able to associate with p21WAF1 in a GST-pull
down assay. All E7 proteins interacted with the CDK inhibitor
with similar efficiency to HPV16 E7, suggesting that the CDK
inhibitor is not active in cells expressing the viral proteins
(Figs. 3A and B). We therefore determined the CDK2 activityin keratinocytes expressing the different viral genes. After
immunoprecipitation of the CDK2 complexes, associated
kinase activity was determined in an in vitro assay using
histone H1 as a substrate. Despite the elevated p21WAF1 levels,
high kinase activity was found to be associated with CDK2
immunopellet in E7-expressing cells (Figs. 4A and B), further
demonstrating that p21WAF1 is inactivated by the viral protein
of these HPV types. Similarly, pRb, which is the endogenous
Fig. 4. Determination of CDK2 activity in E7-expressing keratinocytes. (A and
immunoprecipitated from protein extracts of indicated keratinocytes using an anti-C
(A). The intensities of the bands in two independent experiments were using a Ph
histone H1-kinase activities in E7-expressing cells were normalized to the activitie
keratinocytes. Total protein extracts (50 μg) from cell populations expressing the dif
transferred onto a PVDF membrane and incubated with an anti-phospho-pRB on S
was used as a loading control. (D) Quantification of the increase in pRb phosphoryla
of total and phosphorylated pRb shown in Fig. 3C were quantified as described
phosphorylated forms of pRb to the signal for total pRb, the relative level of pRb
primary keratinocytes (HFK pLXSN).
Fig. 3. HPV26, HPV53 and HPV66 E7 interaction with p21WAF1/CIP1 in GST
pull-down assay. (A) POF cellular extracts (600 μg) was incubated with beads
containing approximately 1 μg of the indicated GST fusion proteins. After
extensive washing of the beads, the amount of p21WAF1/CIP1 associated with the
different GST proteins was determined by immunoblot analysis with a specific
anti-pRb antibody. (B) Signals of immunoblotting of two independent
experiments were quantified by Fluor-STM MultiImager (BioRad).
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E7-expressing keratinocytes in comparison with the control
cells (Figs. 4C and D).
Interestingly, we observed that the serine 608, which has
been reported to be preferentially targeted by the cyclin A/
CDK2 complex (Zarkowska and Mittnacht, 1997; Zarkowska et
al., 1997), is more phosphorylated in cells expressing HPV26
E7 than HPV53 or 66 E7 keratinocytes (Figs. 4C and D). Thus,
the pRb phosphorylation pattern closely correlates with
expression levels of cyclin A (see Figs. 2A and B). Together,
these findings showed that, although with some difference, E7
from HPV26, 53 and 66 proteins alter the intracellular levels
and the activity of cell cycle regulators.
HPV26, 53 or 66 E7 promotes cellular proliferation
Our previous studies have shown that the ability of different
E7 proteins to promote pRb degradation correlates with their
efficiency in overcoming the G1 arrest imposed by p16INK4a
(Giarre et al., 2001). Therefore, we next determined whether
HPV26, 53 and 66 E7 have reduced activity in circumventing the
p16INK4a functions in comparison to HPV16 E7. The experi-B) Histone H1 kinase activity of CDK2 complexes. CDK2 complexes were
DK2 antibody. Kinase activity was determined using histone H1 as substrate
osphorimager scanning (ImageQuant software; Molecular Dynamics) (B). The
s in control cells. (C) Determination of pRb phosphorylation in E7-expressing
ferent viral proteins indicated were applied to an SDS-10% polyacrylamide gel,
er780, Ser795, Ser608, pRB total or -β-tubulin antibody. The β-tubulin signal
tion in primary keratinocytes transduced with indicated retroviruses. The levels
in Materials and methods. After normalization of the levels of the different
phosphorylation in HFK HPV38 E6/E7 cells was evaluated in comparison to
Fig. 5. Efficiency of HPV26, HPV53 and HPV66 E7 in overriding p16INK4a-induced cell cycle arrest. (A) Determination of ectopic expression of p16INK4a in POFs.
One hundred micrograms of protein extracts of cells infected with indicated recombinant retroviruses were applied onto a 15% polyacrylamide-SDS gel, transferred
onto PVDF membrane and incubated with an anti-human p16INK4a or β-actin antibody. (B and C) Ability of HPV26, HPV53 and HPV66 E7 to overcome the p16INK4a
functions. Cells were doubled infected with recombinant retroviruses as indicated in the figure. After 14 days of culture in puromycin-containing medium, colonies
were fixed in 20% methanol and stained with crystal violet. A representative colony formation assay is shown in panel B. Number of colonies was quantified in each
plate by direct counting and normalized considering as 100% the colonies in the pBabe-puro p16INK4a/pLXSN HPV16 E7 plate. The data shown in panel C are the
mean of two independent experiments.
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extremely sensitive to the ectopic expression of p16INK4a
(Malanchi et al., 2004). Co-expression of the viral genes and
p16INK4a was achieved by consecutive retroviral infections.
Reverse transcription polymerase chain reaction (RT-PCR)
showed that all E7 were efficiently expressed (data not
shown), while the ectopic levels of p16INK4a were verified by
immunoblotting (Fig. 5A). The ability of the viral proteins to
overcome the cell cycle arrest imposed by p16INK4a was
determined in a colony-formation assay. As shown in Figs. 5B
and C, expression of p16INK4a alone resulted in a strong decrease
of colony outgrowth, while HPV16 E7 efficiently overcame the
growth inhibition induced by p16INK4a. HPV26, 53 and 66 E7Fig. 6. Growth profiles of keratinocytes expressing the viral proteins. After
selection, the growth of the different cell populations was monitored for more
than 40 days.showed a weaker efficiency in sustaining proliferation in the
presence of p16INK4a.
To further confirm that the E7 proteins from HPV26, 53 and
66 have a weaker activity than HPV16 E7 in promoting cellular
proliferation, we followed the proliferation rate of keratinocytes
expressing the four E7 proteins. In agreement with the fact that
HPKs can only survive in culture for a few population doublings
(PDs), cells transduced with the control empty retrovirus
(pLXSN) entered senescence after few PDs. In contrast, all
keratinocytes expressing the E7 genes continued to proliferate,
although at different rates (Fig. 6). In fact, the HPV16 E7
keratinocytes appeared to grow faster than the cells containing
E7 of the other HPV types. Thus, while HPV26, 53 and 66 E7
proteins promote unscheduled proliferation, it is reduced in
comparison to E7 from HPV16.
Discussion
Although all the cervical cancer-associate mucosal HPV
types belong to the same genus of the HPV phylogenetic tree, a
large number of epidemiological studies have shown that their
carcinogenic potential can differ greatly (Clifford et al., 2005;
Munoz et al., 2003). Transforming activity and ability to evade
the immune system are key properties allowing HPV to induce
cervical cancer. In fact, E6 and E7 of the mucosal HPV types
have developed a number of strategies to evade host immuno-
surveillance, allowing viral persistence and alteration of cell
cycle and apoptosis control, facilitating the transformation of
the infected cells (O'Brien and Campo, 2003). HPV16 is clearly
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of cervical cancers worldwide (Clifford et al., 2005). In a recent
survey three mucosal genus alpha HPV types, 26, 53 and 66,
were classified as probable high-risk types (Munoz et al., 2003).
However, a functional study on the properties of several
mucosal HPV types has revealed that E6 from HPV53 and 66 is
similarly efficient in degrading p53 to E6 from HPV16 or other
mucosal high-risk HPV types (Hiller et al., 2006). In addition,
as shown for HPV16, transfection of primary human keratino-
cytes with the entire genome of HPV53 and 66 led to their
immortalization (Hiller et al., 2006). Thus, the intermediate risk
of these two HPV types for cancer development, as suggested
by the epidemiological studies, may be due to additional
biological properties of E6 and E7.
HPV16 E7 plays a key role in transformation via the
inactivation of pRb functions and consequent stimulation of
E2F-dependent transcription and cell cycle progression (Mun-
ger et al., 2004). Therefore we characterized in detail the effect
of the E7 protein from HPV26, 53 and 66 on the regulation of
the G1/S transition. We observed that all the three E7 proteins
were able to interact with pRb in an in vitro assay. In agreement
with this result, the product of E2F-regulated gene cyclin E was
found to be up-regulated in keratinocytes expressing the
different E7 proteins. Interestingly, the transcription of cyclin
A, another E2F-regulated gene, is efficiently activated by
HPV26 E7. In contrast, only a weak up-regulation of cyclin A
transcript was detected in HPV53 and 66 E7-expressing cells.
These data indicate that the promoters of these two cyclins have
different mechanisms of regulation. The differing effect of these
E7 proteins on the activation of cyclin E and cyclin A
transcription may be explained by their possible difference in
targeting the other pRb-related proteins, p107 and p130
(Dimova and Dyson, 2005). Since it is known that different
E2F complexes are involved in the transcriptional regulation of
cyclin E and cyclin A (Cobrinik, 2005; Zhang et al., 2000), we
would speculate that the HPV26, 53 and 66 E7 may target these
E2F complexes with differing levels of efficiency.
However, independent of their efficiency in up-regulating
cyclin A, the three E7 proteins are capable of stimulating the
proliferation of primary human keratinocytes and overcoming
the G1 cell cycle arrest imposed by overexpression of the CDK
inhibitor p16INK4a to a similar extent. However, they were
clearly less competent than HPV16 E7 in inducing both events.
It is plausible that the relatively high levels of cyclin E render
the cells less dependent on cyclin A. It is more likely, however,
that the cause of their low activity in cell cycle deregulation is
that they do not efficiently induce pRb degradation. Although
the in vitro experiments in keratinocytes showed that expression
of HPV53 and 66 E6 and E7 leads to immortalization, the
inability of E7 to target pRb for degradation may affect the HPV
carcinogenic potential in vivo. Thus, our data provide a possible
explanation for the intermediate risk of HPV26, 53 and 66.
However, since persistence of the viral infection is a key event
in HPV-induced carcinogenesis, it is possible that these HPV
types also have a reduced ability to affect pathways related to
the immune response. Further studies are required to evaluate
this possibility.Materials and methods
Plasmids
All E7 genes were cloned into the retroviral vector pLXSN
(Clontech, BD, Le Pont de Claix, France). The pBabe-puro/
p16INK4a construct was kindly provided by Bruno Amati
(European Institute of Oncology, Milan, Italy). For the produc-
tion of bacterial recombinant proteins, the open reading frames
of the different HPV E7s were cloned into the pGEX-4T1
expression vector (Amersham Biosciences) in frame to the
carboxy-terminal sequence of Schistosoma japonicum glu-
tathione S-transferase (GST).
Cell culture procedures
Phoenix cells, HaCaT cells and human primary oral
fibroblasts (POFs) were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum.
POFs were kindly provided by Pascal Tomakidi (University of
Heidelberg, Germany) and purified as previously described
(Tomakidi et al., 1997, 1998). Human primary keratinocytes
were isolated from foreskin and grown on NIH3T3 feeder
layers in FAD medium containing 3 parts Ham's F12, 1 part
DMEM, 2.5% fetal calf serum, insulin (5 μg/ml), epidermal
growth factor (10 ng/ml), cholera toxin (8.4 ng/ml), adenine
(24 μg/ml) and hydrocortisone (0.4 μg/ml). Feeder layers were
prepared by irradiating NIH3T3 (137Cs; 20 Gy). High-titer
retroviral supernatants were generated by transient transfection
of Phoenix cells (amphotropic viruses) as previously described
(Pear et al., 1993) and used to infect POFs or human
keratinocytes. After infection, POFs or keratinocytes were
selected with 0.5 mg of G418 (for 6 to 8 days) or 0.5 μg of
puromycin (for 4 to 5 days), respectively. Co-expression of the
viral genes and p16INK4a was achieved by consecutive retroviral
infections (Giarre et al., 2001; Malanchi et al., 2004). For the
colony formation, cells were split for selection with puromycin
after p16INK4a or pBabe-puro infection, diluted 10, 100 or 1000
times and grown for 8–10 days as previously described (Vlach
et al., 1996). To visualize the colonies, cells were washed in
PBS, fixed and stained on the plates with crystal violet in 20%
methanol.
Number of colonies in the different plates was normalized to
the positive control plate (pBabe-puro p16INK4a/pLXSN HPV16
E7 that was considered 100%).
For the determination of population doublings, cells were
cultured in 25 cm2 flasks and trypsinized when they reached
approximately 80% confluency (3–4×106cells/ml). Population
doublings were calculated taking into consideration the number
of passages and the split ratio.
Determination of protein half-life
To determine protein half-life, protein synthesis was blocked
by the addition of cycloheximide (10 μg/ml) to the culture me-
dium, and cells were collected at different times (0, 3, 6 and 9 h).
Protein levels were determined by immunoblotting.
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Immunoblot analyses were performed using the following
antibodies: anti-β-tubulin (TUB2.1, Sigma), anti-actin (A4700,
Sigma), anti-p16INK4a (DCS-50, NovoCastra), anti-pRb
(9309SC, Cell Signaling), anti-Phospho-Rb (Ser780) (9307S,
Cell Signaling), anti-Phospho-Rb (Ser795) (9301S, Cell
Signaling), Phospho-Rb (Ser608) (2181S, Cell Signaling),
anti-cyclin E (C-19, Santa Cruz Biotechnology), anti-CDK2
(M2, Santa Cruz Biotechnology), anti-cyclin A (H-432, Santa
Cruz Biotechnology), and anti-p21WAF1/CIP1 (2946, Cell
Signaling) and anti-GST (G7781, Sigma).
Total cellular extractions were performed by lysing the cells
in lysis buffer (20 mM Tris–HCl [pH 8], 200 mM NaCl, 0.5%
Nonidet P-40, 1 mM EDTA, 10 mM NaF, 0.1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, 1 μg of leupeptin/ml and
1 μg of aprotinin/ml) for 30 min at 4 °C. Insoluble materials
were removed by centrifugation (12,000×g, 15 min), the
supernatant was collected and used for immunoblot analysis.
Cell extracts were fractionated by electrophoresis on a sodium
dodecyl sulfate (SDS)-polyacrylamide gel. Proteins were
transferred onto a Polyscreen polyvinylidene difluoride
(PVDF) membrane (NEN Life Sciences) in a Trans-Blot
semidry electrophoretic transfer cell (Bio-Rad) (130 mA, 1 h
30 min). Antigen–antibody complexes were detected by
enhanced chemiluminescence (ECL; Amersham).
For immunoprecipetation experiments, lysates were pre-
cleared with protein A-Sepharose (1 h, 4 °C) and then immuno-
precipated with the anti-CDK2. Immunocomplexes were
washed five times with lysis buffer and analyzed by
immunoblotting.
Kinase assays
CDK2 kinase assays were performed using 100 μg of
keratinocyte lysate. CDK2 complexes were immunoprecipi-
tated using an anti-CDK2 antibody. Immunopellets were
washed three times in lysis buffer and twice in kinase buffer
(17–137, Euromedex) (20 mM MOPS, pH 7.2, 25 mM β
glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovandate,
1 mM dithiothreitol and an inhibitor cocktail (20–116,
Euromedex). Samples were then resuspended in 10 μl of kinase
buffer containing 10 μCi of [-32P]ATP and 1 μMATP (20–113,
Euromedex) and incubated for 30 min at 37 °C in the presence
of 1 μg of histone H1 (20–125, Euromedex). Samples were
subsequently analyzed by SDS-PAGE and autoradiography.
GST pull-down assay
pGEX-4T1/E7 expression constructs were transformed into
E. coli BL21 bacteria, and purification of GST-E7 fusion
proteins was performed as described in the Pharmacia hand-
book. Approximately 0.8 mg of total cell extracts was
incubated with GST/E7 proteins immobilized on Glutathione
beads (approximately 1 μg). After 1 h at 4 °C, the beads were
washed five times in a buffer containing 20 mM Tris–HCl pH
8.0, 200 mM NaCl, 0.5% Nonidet P40, 1 mM EDTA and10 mM NaF. The beads were resuspended in SDS-PAGE
sample buffer, and the eluted proteins were run on an SDS-
polyacrylamide gel.
Total RNA isolation and reverse transcription-PCR analysis
Total RNAwas isolated using the Absolutely RNAMiniprep
Kit (Stratagene). cDNAs were synthesized from 1 μg of total
RNA samples by reverse transcription using the first strand
cDNA synthesis kit (MBI Fermentas-Euromedex), and PCR
was performed using the following primers: 5′-AAG GTG GTG
AAG CAG GCG T-3′ (forward) and 5′-GAG GAG TGG GTG
TCG CTG TT-3′ (reverse) for GAPDH, 5′-CAA CCC GAA
ATT GAC CTA CG-3′ (forward) and 5′-TTC TGT CGA CTG
CTC TGC AC-3′ (reverse) for HPV26 E7, 5′-CAA TGC CAT
GAG CAA TTG AA-3′ and 5′-ACT GCA CCA ACG ACT
CACAC-3′ (reverse) for HPV53, 5′-GGA CAG CTC AGA
GGATGA GG-3′ (forward) and 5′-TTA GAT GAT GCG CAG
AGT GG-3′ (reverse) for HPV66, 5′-CAG CTC AGA GGA
GGA GGATG-3′ (forward) and 5′-GCC CAT TAA CAG GTC
TTC CA-3′ (reverse).
Quantitative RT-PCR
Real-time PCR analysis was performed using the Light-
Cycler® FastStart DNA MasterPLUS SYBR Green I kit (Roche
Molecular Biochemicals, Mannheim, Germany) in a Light-
Cycler fluorescence temperature cycler (Roche) according to
the manufacturer's instructions and the following primers: 5′-
TTA TTG CTG GAGCTG CCT TT-3′ (forward) and 5′-CTC
TGG TGG GTT GAG GAG AG-3′ (reverse) for cyclin A, 5′-
GCA TCC TCA CCC TGA AGT A-3′ (forward) and 5′-CAG
AGG CGT ACA GGG ATA G-3′ (reverse) for β-actin.
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